Clinical trial of minocycline hydrochloride combined with vitapex paste in the treatment of persistent apical periodontitis

Abstract

Abstract:

AIM: To observe the clinical efficacy and safety of minocycline hydrochloride combined with vitapex paste in the treatment of persistent apical periodontitis. METHODS: One hundred and two patients with persistent apical periodontitis were divided into control group (n=51) and treatment group (n=51) according to random number table method. The control group was treated with calcium hydroxide iodoform paste, and the treatment group was treated with vitapex paste a root canal combined with minocycline hydrochloride ointment. After 2 weeks and 3 months treatment, the clinical curative effect and adverse reaction were observed, the degree of pain was evaluated by visual analogue scale (VAS), and the levels of peripheral inflammatory factor were detected by ELISA. RESULTS: After two weeks, the total effective rate in treatment group was significantly higher than the control group (χ²=6.411, P=0.011). After 3 months, the total effective rate 94.12% in treatment group was significantly higher than the control group 70.59%(χ²=9.714, P=0.002). After treatment the VAS was lower than before treatment in two groups, the VAS of 3 months was significantly less than 2 weeks, and the VAS in treatment group was obvious lower than the control group, the difference was statistically significant (P<0.01). After treatment the levels of TNF-α, IL-2 and IL-8 were lower than before treatment in two groups, the levels of TNF-α, IL-2 and IL-8 of 3 months were significantly less than 2 weeks, and the treatment group was obvious lower than the control group, the difference was statistically significant (P<0.05). Two groups of patients were not seen obvious adverse reactions and discomfort symptoms. CONCLUSION: The minocycline hydrochloride combined with vitapex paste in the treatment of persistent apical periodontitis can reduce the patient's pain, decrease inflammation, increase clinical efficacy, and is relatively safe, which is worthy of popularization and application.

Key words: persistent apical periodontitis, minocycline hydrochloride, vitapex paste, clinical curative, adverse reactions

CLC Number:

R781.34

ZHOU Shuzhen, GAO Yunyun, XIE Jing, GAO Mengfei. Clinical trial of minocycline hydrochloride combined with vitapex paste in the treatment of persistent apical periodontitis[J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2017, 22(2): 170-173.

References

［1］Saoud TM, Huang GT, Gibbs JL,et al. Management of teeth with persistent apical periodontitis after root canal treatment using regenerative endodontic therapy［J］. J Endod, 2015, 41(10):1743-1748.
［2］申静,张海峰,靳淑凤,等.54例持续性根尖周炎的显微根尖外科手术1年疗效观察［J］.华西口腔医学杂志,2012,30(4):388-392.
［3］ Estrela C, Decurcio Dde A, Silva JA, et al. Immune-inflammatory cell profile and receptor activator of nuclear factor kappa B ligand/osteoprotegerin expression in persistent apical periodontitis after root canal retreatment failure［J］. J Endod, 2016 ,42(3):439-446.
［4］张大风,黄盛斌,张友婷,等.盐酸米诺环素软膏联合替硝唑治疗慢性牙周炎的临床疗效及安全性研究［J］.中国临床药理学杂志,2015,31(8):590-591,594.
［5］岳林.牙体牙髓病临床问题解析Ⅵ：根尖周炎临床诊断和预后与组织病理学表现的相关性(二)［J］.中华口腔医学杂志,2010,45(4):245-248.
［6］岳林.牙体牙髓临床问题解析Ⅴ：根尖周炎临床诊断和预后与组织病理学表现的相关性(一)［J］.中华口腔医学杂志,2010,45(3):177-181.
［7］Voutilainen A, Pitkaho T, Kvist T, et al. How to ask about patient satisfaction? The visual analogue scale is less vulnerable to confounding factors and ceiling effect than a symmetric Likert scale［J］. J Adv Nurs, 2016,72(4):946-957.
［8］彭颖,王金生,刘焱,等.Vitapex 糊剂治疗乳牙有瘘型慢性根尖周炎的临床效果观察［J］.白求恩医学杂志,2016,14(1):12-13.
［9］谢文.Vitapex糊剂一次法根管治疗儿童有窦型慢性根尖周炎的临床疗效［J］.牡丹江医学院学报,2016,37(2):33-35.
［10］姚金姗.米诺环素软膏联合Vitapex在窦道型根尖周炎治疗中的应用价值分析［J］.中国伤残医学,2016,24(5):96-97.
［11］尹敏,黄林江,宣桂红,等.盐酸米诺环素软膏配合康复新液漱口对慢性牙周炎患者龈沟液IL-8和TNF-α水平的影响研究［J］.中国生化药物杂志,2016,36(5):166-168.

[1]	LI Xinyu, HUANG Xin. State of clinical application of meloxicam [J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2023, 28(2): 189-197.
[2]	HUANG Yiting, SHEN Aizong. Clinical research progress of afatinib therapy for lung cancer [J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2021, 26(4): 474-480.
[3]	XING Kai, GONG Jinyu, LUO Jianquan. Advances on pharmacogenomics of diuretics-related adverse reactions [J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2021, 26(2): 204-212.
[4]	ZHANG Lu, LIN Liangmo, LIU Keke, HUANG Yamin, HUANG Xingxing, YANG Yongyu, XIAO Jian. Therapeutic drug monitoring and pharmacokinetics of new coronavirus pneumonia antiviral drugs [J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2020, 25(5): 566-575.
[5]	. Research progress of linezolid-induced lactic acidosis [J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2020, 25(12): 1408-1413.
[6]	WANG Mengzhi, WEI Yuguang, HUANG Xiaoling. Analysis of rational usage of meropenem in our hospital [J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2018, 23(8): 937-941.
[7]	SONG Xiujuan，LIN Yongjian，WANG Lina，XU Huiqin，LIU Xiaoli. Effect of oxiracetam combined with Cistanche yizhi capsule in treating cognitive disorder from leukoaraiosis [J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2017, 22(2): 184-189.
[8]	LI Su-xia, YANG Xiao-lei, CHEN Su-xiu, LIU Jie-fan, QUAN Shi-chao. Efficacy and safety of gefitinib treated elded-patients with advanced non-small cell lung cancer [J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2013, 18(12): 1410-1413.
[9]	LUO Jian-quan, ZHANG Wei. Research progress on human leucocyte antigen gene polymorphisms and drug adverse reactions [J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2012, 17(7): 828-834.
[10]	CHEN Qi-Kui, YUAN Shi-Zheng, ZHONG Ying-Qiang, LI Cu-Jun, WU Hui-Sheng. Clinical evaluation of sulfasalazine in the treatment of patients with mild and moderate ulcerative colitis [J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2004, 9(9): 1007-1010.